Novo Nordisk’s Wegovy Pill Now Broadly Available Across the U.S.

Novo Nordisk has officially launched its much‑anticipated **Wegovy oral weight‑loss pill**, making it widely available by prescription across the United States after receiving approval from the U.S. Food and Drug Administration late last year. This once‑daily **pill is the first GLP‑1 weight‑loss medication that can be taken orally**, offering an alternative to the weekly injectable forms that have dominated the market. Patients can now fill prescriptions for Wegovy at more than 70,000 pharmacies nationwide and through telehealth services, with doses ranging from 1.5 mg to 25 mg. Clinical trial data showed users of the oral Wegovy pill achieved significant weight loss — around 16.6% on average at 64 weeks of consistent use — when combined with a reduced‑calorie diet and increased physical activity. Pricing for self‑pay patients starts at approximately $149 per month for the starter dose, with higher doses priced up to $299 per month. Many commercially insured patients may pay as little as $25 per month with savings offers, improving affordability for eligible patients. Novo Nordisk’s launch comes amid intense industry competition as rivals like Eli Lilly are also pursuing oral GLP‑1 weight‑loss drugs. The new pill is expected to expand access to effective obesity treatment, particularly for patients who prefer pills over injections and seek more convenient daily use. #Wegovy #WeightLossPill #NovoNordisk #GLP1 #SlimScan #GrowthStocks #CANSLIM